Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29722901 | 0.79 | CXCR2 (0.43) | LMNANPC1CASP3RAB9ASMN1; SMN2 | |
| SCHEMBL777305 | 0.79 | CXCR2 (0.43) | LMNANPC1CASP3RAB9ASMN1; SMN2 | |
| SCHEMBL1802193 | 0.79 | HTR7 (0.57) | HTR7MAOAMAOBLMNANOS3 | |
| SCHEMBL31381572 | 0.77 | HTR7 (0.33) | HTR7MAOAMAOBLMNAALDH1A1 | |
| SCHEMBL2784023 | 0.77 | HTR7 (0.33) | HTR7MAOAMAOBLMNAALDH1A1 | |
| SCHEMBL31381759 | 0.77 | HTR7 (0.33) | HTR7MAOAMAOB | |
| SCHEMBL31413592 | 0.77 | MAOA (0.41) | HTR7MAOAMAOB | |
| SCHEMBL943477 | 0.76 | APOBEC3G (0.33) | HTR7MAOAMAOB | |
| SCHEMBL21282025 | 0.76 | HTR7 (0.38) | HTR7MAOAMAOBLMNANOS3 | |
| SCHEMBL30127898 | 0.76 | GABRA1 (0.35) | HTR7MAOAMAOBLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| US-12473272-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| CN-115925693-B | JAK1 selective inhibitors | 阿斯利康(瑞典)有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-27 | — | — | US | disclosed |
| US-11897869-B2 | JAK1 selective inhibitors | ASTAZENECA AB (SE) | 2024-02-13 | — | — | US | disclosed |
| EP-4219470-A1 | JAK1 SELECTIVE INHIBITORS | Astrazeneca AB (SE) | 2023-08-02 | — | — | EP | disclosed |
| CN-115925693-A | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3571192-B1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2022-11-30 | — | — | EP | disclosed |
| CN-110461830-B | Selective inhibitors of JAK1 | 阿斯利康(瑞典)有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA PHARMACEUTICALS LP | 2021-06-24 | — | — | US | disclosed |
| US-10961228-B2 | JAK1 selective inhibitors | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| WO-2018134213-A1 | JAK1 SELECTIVE INHIBITORS | ASTRAZENECA AB (SE) | 2018-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473272-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | HTR7 1735/4885MAOA 4188/4885MAOB 3685/4885 |
| US-11897869-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | HTR7 1735/4885MAOA 4188/4885MAOB 3685/4885 |
| US-20260028329-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | HTR7 1955/4885MAOA 3628/4885MAOB 3552/4885 |
| US-20240208947-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | HTR7 1735/4885MAOA 4188/4885MAOB 3685/4885 |
| US-20210188821-A1 | JAK1 SELECTIVE INHIBITORS | JAK1, JAK2, JAK3 | HTR7 1735/4885MAOA 4188/4885MAOB 3685/4885 |
| US-10961228-B2 | JAK1 selective inhibitors | JAK1, JAK2, JAK3 | HTR7 1735/4885MAOA 4188/4885MAOB 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.